340 related articles for article (PubMed ID: 27841689)
1. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
Vandoolaeghe P; Schuerman L
Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
[TBL] [Abstract][Full Text] [Related]
2. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
Vandoolaeghe P; Schuerman L
Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
[TBL] [Abstract][Full Text] [Related]
3. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
5. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
[TBL] [Abstract][Full Text] [Related]
6. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.
Regules JA; Cicatelli SB; Bennett JW; Paolino KM; Twomey PS; Moon JE; Kathcart AK; Hauns KD; Komisar JL; Qabar AN; Davidson SA; Dutta S; Griffith ME; Magee CD; Wojnarski M; Livezey JR; Kress AT; Waterman PE; Jongert E; Wille-Reece U; Volkmuth W; Emerling D; Robinson WH; Lievens M; Morelle D; Lee CK; Yassin-Rajkumar B; Weltzin R; Cohen J; Paris RM; Waters NC; Birkett AJ; Kaslow DC; Ballou WR; Ockenhouse CF; Vekemans J
J Infect Dis; 2016 Sep; 214(5):762-71. PubMed ID: 27296848
[TBL] [Abstract][Full Text] [Related]
7. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
Penny MA; Pemberton-Ross P; Smith TA
Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
[TBL] [Abstract][Full Text] [Related]
12. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
Kaslow DC; Biernaux S
Vaccine; 2015 Dec; 33(52):7425-32. PubMed ID: 26431982
[TBL] [Abstract][Full Text] [Related]
13. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
[TBL] [Abstract][Full Text] [Related]
14. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
[TBL] [Abstract][Full Text] [Related]
15. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
[TBL] [Abstract][Full Text] [Related]
17. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.
Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P
N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
RTS,S Clinical Trials Partnership
PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
